September 15, 2015
The Ministry of Health, Labor and Welfare said on September 14 that it has granted orphan drug designations to three compounds including Chugai Pharmaceutical’s bevacizumab (recombinant) for the treatment of cervical cancer. The two other compounds are Otsuka Pharmaceutical’s ponatinib...read more